Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

Mineralys Therapeutics (NASDAQ: MLYS) will repurchase all future lorundrostat royalties owed to Tanabe for $200 million upfront plus up to $100 million in commercial milestone payments.

Rhea-AI Summary

Mineralys Therapeutics (NASDAQ: MLYS) will repurchase all future lorundrostat royalties owed to Tanabe for $200 million upfront plus up to $100 million in commercial milestone payments. Aggregate remaining milestone obligations total up to $265 million. Tanabe will also assign lorundrostat IP rights to Mineralys.

The company entered a $500 million senior secured term loan with Pharmakon, with $100 million funded at closing, maturing in June 2031 at SOFR (3.25% floor) + 5.50%. Mineralys also priced an underwritten $150 million common stock offering.

Positive

• Royalty obligation on lorundrostat repurchased for $200 million upfront plus up to $100 million in milestones
• Future milestone obligations to Tanabe capped at up to $265 million
• Tanabe to assign lorundrostat intellectual property rights to Mineralys
• Access to up to $500 million senior secured term loan from Pharmakon
• $100 million term loan tranche funded at closing to support liquidity
• Approximately $150 million underwritten common stock offering priced to raise equity capital

Negative

• Royalty repurchase requires $200 million immediate cash payment and potential $100 million extra on milestones
• Term loan adds up to $500 million of secured debt to the capital structure
• Loan bears interest at SOFR with 3.25% floor plus 5.50% margin, increasing financing costs
• Term loan matures in June 2031, creating a sizable future refinancing or repayment obligation
• Approximately $150 million common stock offering will dilute existing shareholders

Argus Jun 3 session

-13.14% close to close Open Argus

Details

News Market Reaction – MLYS

On Jun 3, the day this news came out, MLYS closed 13.14% below the previous close.

Data tracked by StockTitan Argus for the Jun 3 session.

Market Context

On Jun 3, the day this news came out, the stock closed 13.1% below the previous close. A negative re...

Analysis

On Jun 3, the day this news came out, the stock closed 13.1% below the previous close. A negative reaction despite the royalty buyout fits a pattern where financing-heavy announcements weigh on shares. Today’s news combines a $200 million upfront royalty repurchase, up to $100 million in milestones, a $500 million senior secured term loan and a $150.0 million common stock offering. This adds leverage and equity issuance to a company that recently reported ongoing net losses, and may raise concerns about dilution and debt service even as it simplifies future economics for lorundrostat.

Key Figures

Royalty repurchase upfront: $200 million Additional milestones: Up to $100 million Aggregate future milestones: Up to $265 million +5 more

Royalty repurchase upfront

$200 million

Upfront payment to repurchase lorundrostat royalty obligation from Tanabe

Additional milestones

Up to $100 million

New commercial milestone payments to Tanabe under revised arrangement

Aggregate future milestones

Up to $265 million

Total potential future milestone payments to Tanabe after transaction

Existing commercial milestones

$165 million

Remaining existing commercial milestones owed to Tanabe

Second indication milestone

Up to $10 million

Milestones tied to commercialization in a second indication

Term loan commitment

$500 million

Committed senior secured term loan facility from Pharmakon-managed funds

Initial loan funding

$100 million

First tranche funded at closing under the term loan

Common stock offering size

$150.0 million

Approximate size of underwritten common stock offering

Historical Context

5 past events · Latest: May 27

5 events

1. May 27

   Conference participation

   24h Move

   +0.1%

   Management participation at Jefferies 2026 Global Healthcare Conference.

2. May 18

   Clinical data update

   24h Move

   -0.5%

   Announcement of upcoming Phase 3 Launch-HTN lorundrostat data presentation.

3. May 06

   Earnings and NDA

   24h Move

   -2.6%

   Q1 2026 results plus FDA acceptance of lorundrostat NDA with set PDUFA date.

4. May 05

   Inducement grants

   24h Move

   +2.9%

   Equity inducement awards to new non-executive employees under incentive plan.

5. May 05

   Conference participation

   24h Move

   -1.3%

   Participation in Bank of America Securities 2026 Health Care Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

royalty, senior secured term loan facility, secured overnight financing rate (SOFR), Form 8-K, +1 more

5 terms

royalty financial

"Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million"

A royalty is a payment made to the owner of a resource or asset—such as a patent, mineral rights, or creative work—whenever others use or profit from it. For investors, royalties provide a steady stream of income without owning the entire asset, similar to earning a small commission each time a product is sold or a service is used. This makes royalties an important factor in valuing certain types of investments.

senior secured term loan facility financial

"$500 million committed under senior secured term loan facility from funds managed"

A senior secured term loan facility is a type of borrowed money that a company takes out, which is backed by its valuable assets like property or equipment. Because it is secured by these assets and ranks higher in repayment priority, it is considered safer for lenders and typically offers lower interest rates. For investors, it provides a relatively stable and priority claim on the company's assets if it encounters financial difficulties.

secured overnight financing rate (SOFR) financial

"The term loan bears interest at a rate based upon the secured overnight financing rate (SOFR)"

A secured overnight financing rate (SOFR) is the interest rate on very short, one‑day loans that are backed by high‑quality collateral (like government bonds), so lenders face less risk. Investors care because SOFR is a widely used benchmark that sets the cost of borrowing and the pricing of loans, bonds and derivatives; think of it as a trusted yardstick for short‑term interest costs that influences returns and valuations across markets.

Form 8-K regulatory

"details ... will be filed with the SEC on a Current Report on Form 8-K"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

common stock offering financial

"Mineralys also priced an underwritten offering of approximately $150.0 million of its common stock."

A common stock offering is when a company sells additional shares of its ordinary ownership to the public or existing shareholders to raise cash. For investors it matters because selling more shares is like cutting the company’s pie into more pieces — it can fund growth or pay down debt, but it usually reduces each existing shareholder’s slice and can put downward pressure on the share price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met –

– $500 million committed under senior secured term loan facility from funds managed by Pharmakon Advisors, LP –

      – Priced $150 million Common Stock Offering –

RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced the repurchase of all potential future royalty payments due to Tanabe Pharma Corporation (Tanabe) related to lorundrostat in exchange for a $200 million upfront payment and up to $100 million once certain commercial milestones are met. Concurrently with the royalty repurchase, the Company announced entering into a $500 million committed debt facility with funds managed by Pharmakon Advisors, LP, of which $100 million will be funded at closing. In addition, Mineralys separately announced the pricing of an underwritten offering of approximately $150.0 million of its shares of common stock.  

“The transaction with Tanabe eliminates all future royalty payments under the license agreement and positions Mineralys to capture meaningful incremental value from future potential sales of lorundrostat,” said Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. “The $100 million proceeds funded by Pharmakon at close, combined with the additional $400 million in additional capital from Pharmakon, meaningfully strengthens our balance sheet and access to capital.”

Repurchase of Lorundrostat Royalty Obligation under Tanabe License Agreement
Mineralys will pay Tanabe $200 million upfront and up to $100 million once certain commercial milestones are met to extinguish its existing royalty obligation for lorundrostat. As a result, Mineralys’ aggregate potential future milestone payments to Tanabe will be up to $265 million, including:

• $100 million in new commercial milestones
• $165 million in existing commercial milestones, including up to $10 million related to commercialization in a second indication

Tanabe has also agreed to subsequently assign to Mineralys its intellectual property rights related to lorundrostat.  

Senior Secured Loan
Mineralys has entered into an up to $500 million senior secured term loan agreement with funds managed by Pharmakon. The term loan will be available to Mineralys in four tranches, with the first tranche of $100 million to be funded upon closing. Drawdowns at each tranche are subject to customary conditions. The five-year term loan matures in June 2031. The term loan bears interest at a rate based upon the secured overnight financing rate (SOFR), subject to a SOFR floor of 3.25%, plus a margin of 5.50% per annum.

Additional details of the repurchase of the lorundrostat royalty obligation under the Tanabe license agreement (the License Agreement) and the secured term loan will be filed with the SEC on a Current Report on Form 8-K.

Common Stock Offering
As separately announced, Mineralys also priced an underwritten offering of approximately $150.0 million of its common stock.

About Mineralys Therapeutics
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.

About Pharmakon Advisors

Pharmakon Advisors, LP is a leading investor in non-dilutive debt for the life sciences industry and is the investment manager of the BioPharma Credit funds. Established in 2009, funds managed by Pharmakon Advisors, LP have committed up to $12 billion across 76 investments.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on Mineralys’ current beliefs and expectations and include, but are not limited to, statements regarding: Mineralys’ expectations with respect to finalizing an agreement with Tanabe to terminate the License Agreement and to have Tanabe’s rights in the licensed intellectual property related to lorundrostat transferred to Mineralys, and the capital available under the secured debt facility, including the potential for Mineralys to draw down additional tranches thereunder. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Mineralys’ business, including, without limitation: any delays in the FDA’s review of Mineralys’ accepted NDA, including as a result of a government shutdown or reductions in agency funding or personnel; the results of Mineralys’ clinical trials, including the Advance-HTN and Launch-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for regulatory approval of lorundrostat; later developments with the FDA may be inconsistent with the feedback from prior meetings, including whether the proposed pivotal program will support registration of lorundrostat following the FDA’s review of Mineralys’ NDA submission; the risk that the funding under the secured debt facility may not be completed on the timeframe Mineralys expects, or at all, including as a result of its failure to meet the conditions required for such funding or failure to comply with the affirmative and negative covenants under the debt facility; Mineralys may not be able to reach agreement on the proposed termination of the License Agreement on its expected timeframe, or at all; Mineralys’ future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; Mineralys’ dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs and other trade policies, and the potential for a local and/or global economic recession; Mineralys’ ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; Mineralys’ reliance on its exclusive license with Tanabe to provide Mineralys with intellectual property rights to develop and commercialize lorundrostat; and other risks described in Mineralys’ filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Mineralys undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contacts

Investor Relations
investorrelations@mineralystx.com

Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mineralys Therapeutics (NASDAQ: MLYS) announce about the Tanabe lorundrostat royalties on June 3, 2026?

Mineralys announced it will repurchase all future lorundrostat royalties owed to Tanabe. According to Mineralys, the company will pay $200 million upfront plus up to $100 million in commercial milestones, capping aggregate remaining milestone obligations at up to $265 million.

How much is Mineralys paying to repurchase lorundrostat royalty obligations from Tanabe?

Mineralys is paying $200 million upfront and up to $100 million in commercial milestones to extinguish the royalty. According to Mineralys, this structure leaves up to $265 million in aggregate future milestone payments, including $100 million in new and $165 million existing commercial milestones.

What are the key terms of the $500 million Pharmakon loan facility for Mineralys Therapeutics (MLYS)?

Mineralys secured an up to $500 million senior secured term loan from funds managed by Pharmakon. According to Mineralys, the five-year loan matures in June 2031, is available in four tranches, and bears interest at SOFR (3.25% floor) plus a 5.50% annual margin.

How much funding will Mineralys receive at closing from the Pharmakon debt facility?

Mineralys will receive an initial $100 million tranche at closing from the Pharmakon term loan. According to Mineralys, additional drawdowns of the remaining $400 million across later tranches are subject to customary conditions, providing staged access to further capital over time.

What is the size of the Mineralys Therapeutics (MLYS) common stock offering announced with the financing?

Mineralys separately priced an underwritten offering of approximately $150 million of its common stock. According to Mineralys, this equity raise runs alongside the $500 million term loan and the royalty repurchase, further strengthening the company’s overall capital resources and funding flexibility.

What happens to lorundrostat intellectual property rights after the Tanabe royalty repurchase by Mineralys?

Following the royalty repurchase, Tanabe has agreed to assign its lorundrostat intellectual property rights to Mineralys. According to Mineralys, this assignment consolidates ownership of lorundrostat IP with the company, aligning with its strategy around future potential commercialization of the therapy.